The global viral clearance market revenue was around US$ 462.5 million in 2022 and is estimated to reach US$ 971.8 million by 2031, growing at a compound annual growth rate (CAGR) of 8.6% during the forecast period from 2023 to 2031.
Viral clearance is an important process in the development of monoclonal antibodies, glycoproteins, recombinant proteins, medical devices, and tissue and blood-derived products. This is due to these products are at threat of contamination by fungi, bacteria, viruses, and chemical impurities.
Market Driving Factors
Investments in research and development activities, especially in the life sciences sector, are playing a substantial role in boosting market expansion. In addition, pharmaceutical companies and contract research organizations are engaging in partnerships to create and enhance viral clearance methods to fulfill the evolving needs of the market.
Increasing technological advancements are estimated to boost market growth. Technological evolution in the medical field surges the demand for viral clearance process and creates new & improved therapies to tackle the increase in various diseases such as nanofiltration technology.
Increasing awareness about viral safety in the healthcare industry is estimated to propel market growth. The significance of viral safety in the healthcare sector has been owing to the increasing prevalence of viral diseases such as hepatitis, Human Immunodeficiency Virus (HIV), and Zika virus. As a result, regulatory agencies such as European Medicines Agency (EMA), and Food and Drug Administration (FDA) have executed strict regulations and policies surrounding the security of biopharmaceutical products.
The high expense of developing new products and technologies, along with a shortage of qualified personnel, is impeding the market expansion.
Regional Analysis
North America dominated the market in terms of the largest share and maintained its dominance throughout the projection period. This can be mainly attributed to a surge in demand for biopharmaceuticals and an upsurge in demand for cutting-edge technologies in the purification of recombinant proteins made by animal cell cultures to make high-value products of modern biotechnology.
Asia Pacific is estimated to dominate the market in terms of the fastest revenue growth rate during the projection period. This is mainly due to the increasing population and demand for biopharmaceutical products and raising awareness of chronic diseases. Additionally, favorable government policies, such as research grants and tax breaks also anticipated to boost the market growth in this region.
Segmentation Insights
Application Insight
The cellular and gene therapy products segment is estimated to dominate the market in terms of growth rate. This is owing to the surge in the number of clinical trials of cellular and gene therapy products. In addition, raising investments of pharmaceutical companies in the development of new drugs is boosting the viral clearance services.
The vaccine segment dominates the market in terms of revenue. This is mainly due to the pandemic. In addition, people realize the significance of good health and have become aware of their health. As a result, surging demand for the production of vaccines and immunization against chronic illnesses such as cervical cancer, hepatitis, and others is boosting the demand of the segment.
End User Insight
The pharmaceutical and biotechnology companies segment dominated the market and is estimated to continue its dominance during the projection period. This is due to the surge in the utilization of viral clearance processing during the production of biopharmaceuticals. Furthermore, market players are adopting several key strategies to extend their business and increase investment in R&D.
Prominent Companies
Segmentation Outline
The global viral clearance market segmentation focuses on the Method, Application, End User, and Region.
By Method
By Application
By End User
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL VIRAL CLEARANCE MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: VIRAL CLEARANCE MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL VIRAL CLEARANCE MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL VIRAL CLEARANCE MARKET, BY METHOD
5.1 OVERVIEW
5.2 VIRAL REMOVAL
5.2.1 CHROMATOGRAPHY
5.2.2 NANOFILTRATION
5.2.3 PRECIPITATION
5.3 VIRAL INACTIVATION
5.3.1 LOW PH
5.3.2 SOLVENT DETERGENT METHOD
5.3.3 HEAT PASTEURIZATION
5.3.4 OTHERS
6 GLOBAL VIRAL CLEARANCE MARKET, BY APPLICATION
6.1 OVERVIEW
6.2 RECOMBINANT PROTEINS
6.3 BLOOD AND BLOOD PRODUCTS
6.4 CELLULAR AND GENE THERAPY PRODUCTS
6.5 VACCINE
6.6 OTHERS
7 GLOBAL VIRAL CLEARANCE MARKET, BY END USER
7.1 OVERVIEW
7.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
7.3 CONTRACT RESEARCH ORGANIZATIONS
7.4 ACADEMIC RESEARCH INSTITUTES
7.5 OTHERS
8 GLOBAL VIRAL CLEARANCE MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3.1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL VIRAL CLEARANCE MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
9.4 COMPETITIVE DASHBOARD
9.5 PRODUCT MAPPING
9.6 TOP PLAYER POSITIONING, 2022
9.7 COMPETITIVE HEATMAP
9.8 TOP WINNING STRATEGIES
10 COMPANY PROFILES
10.1 CREATIVE BIOGENE
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.2 WUXI BIOLOGICS INC.
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.3 ALLURE MEDICAL GROUP
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.4 EUROFINS SCIENTIFIC
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.5 SARTORIUS STEDIM BIOTECH
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.6 MERCK KGAA
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.7 SYNGENE INTERNATIONAL LIMITED
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.8 MARAVAI LIFESCIENCES HOLDINGS INC.
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.9 CHARLES RIVER LABORATORIES INTERNATIONAL INC.
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.10 CLEAN CELLS
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved